The current study was conducted to evaluate the antihyperglycemic and antidyslipidemic effects of Withania adpressa aqueous extract (WAAE) in 2 experimental animal models. In streptozotocin-induced diabetic rats, daily oral administration of WAAE at a dose of 20 mg/kg for 15 days significantly reduced fasting blood glucose, improved plasma lipid profile, increased hepatic, muscle glycogen content and enhanced liver histological architecture. In another model of tyloxapol-induced hyperlipidemia, a single oral dose of WAAE at 400 mg/kg significantly reduced plasma concentrations of total cholesterol, triglycerides and LDL-c without affecting HDL-c levels. These results highlight the promising therapeutic potential of Withania adpressa in managing metabolic disorders such as diabetes and dyslipidemia.